Nanomaterials · 7 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review evaluates polymer-based nanoparticles as drug delivery systems for purine drugs used in cancer and viral infections. The central finding is that these nanoparticles can enhance drug efficacy and reduce toxicity in preclinical models, but significant research gaps remain for clinical application.
This narrative review synthesizes preclinical research on polymer-based nanoparticles (NPs) as delivery systems for purine drugs like acyclovir, tenofovir, and 6-mercaptopurine. The review covers in vitro and animal model studies, noting that NPs can improve pharmacokinetic properties, such as half-life and bioavailability, and enhance drug targeting to specific organs or cells. Key reported achievements include prolonged survival in a mouse leukemia model for 6-mercaptopurine and reduced toxicity for several drugs. The authors conclude that while NPs show promise, their safety, especially for positively charged carriers, and the need for individualized formulation assessment require further study before clinical translation.
